BACKGROUND: The p53 protein, a well-known tumor suppressor that functions primarily as a transcription factor, initiates cell cycle arrest and apoptosis after genotoxic stress. The antiapoptotic regulator Bcl-2 is a downstream modulator of p53-induced apoptosis. Loss of function of the p53 tumor suppressor through mutation is an important event that contributes to cellular transformation. Mutation of p53 is one of the most common genetic alterations in squamous cell carcinomas of the head and neck (SCCHN). We hypothesized that p53 mutation is associated with Bcl-2 expression and susceptibility to apoptosis in SCCHN. METHODS: Exons 5 to 8 of the p53 gene were sequenced in 22 SCCHN tumor samples and correlated with the Bcl-2 expression and apoptosis rates in these tumors. In addition, a Bcl-2-expressing SCCHN cell line, UMSCC74B, was stably transfected with a temperature-sensitive mutant p53 construct, and Bcl-2 expression levels were examined at the mutant and the wild-type temperatures. RESULTS: Bcl-2 expression was inversely correlated with wild-type p53 status in SCCHN tumors (p = .05). Furthermore, there was a modest increase (1.7-fold) in apoptosis in the wild-type p53 tumors compared with mutant p53 SCCHN. Immunoblotting of UMSCC74B cells stably transfected with the temperature-sensitive mutant p53 construct demonstrated that shifting these cells to the mutant p53 temperature (39.5 degrees C) resulted in decreased expression of Bcl-2 compared with levels in cells grown at the wild-type p53 temperature (32.5 degrees C). Further investigation showed that SCCHN cells expressing predominantly mutant p53 and decreased Bcl-2 were more susceptible to cisplatin-induced apoptosis than vector-transfected controls (p < .0001). CONCLUSIONS: These results suggest that p53 mutation directly modulates Bcl-2 expression and therefore susceptibility to chemotherapy-induced apoptosis in SCCHN cells in vitro. (c) 2004 Wiley Periodicals, Inc.
BACKGROUND: The p53 protein, a well-known tumor suppressor that functions primarily as a transcription factor, initiates cell cycle arrest and apoptosis after genotoxic stress. The antiapoptotic regulator Bcl-2 is a downstream modulator of p53-induced apoptosis. Loss of function of the p53tumor suppressor through mutation is an important event that contributes to cellular transformation. Mutation of p53 is one of the most common genetic alterations in squamous cell carcinomas of the head and neck (SCCHN). We hypothesized that p53 mutation is associated with Bcl-2 expression and susceptibility to apoptosis in SCCHN. METHODS: Exons 5 to 8 of the p53 gene were sequenced in 22 SCCHN tumor samples and correlated with the Bcl-2 expression and apoptosis rates in these tumors. In addition, a Bcl-2-expressing SCCHN cell line, UMSCC74B, was stably transfected with a temperature-sensitive mutant p53 construct, and Bcl-2 expression levels were examined at the mutant and the wild-type temperatures. RESULTS:Bcl-2 expression was inversely correlated with wild-type p53 status in SCCHN tumors (p = .05). Furthermore, there was a modest increase (1.7-fold) in apoptosis in the wild-type p53tumors compared with mutant p53 SCCHN. Immunoblotting of UMSCC74B cells stably transfected with the temperature-sensitive mutant p53 construct demonstrated that shifting these cells to the mutant p53 temperature (39.5 degrees C) resulted in decreased expression of Bcl-2 compared with levels in cells grown at the wild-type p53 temperature (32.5 degrees C). Further investigation showed that SCCHN cells expressing predominantly mutant p53 and decreased Bcl-2 were more susceptible to cisplatin-induced apoptosis than vector-transfected controls (p < .0001). CONCLUSIONS: These results suggest that p53 mutation directly modulates Bcl-2 expression and therefore susceptibility to chemotherapy-induced apoptosis in SCCHN cells in vitro. (c) 2004 Wiley Periodicals, Inc.
Authors: Mysore S Veena; Reason Wilken; Jun-Ying Zheng; Ankur Gholkar; Natarajan Venkatesan; Darshni Vira; Sameer Ahmed; Saroj K Basak; Clifton L Dalgard; Sandhiya Ravichandran; Raj K Batra; Noriyuki Kasahara; David Elashoff; Michael C Fishbein; Julian P Whitelegge; Jorge Z Torres; Marilene B Wang; Eri S Srivatsan Journal: J Biol Chem Date: 2014-10-20 Impact factor: 5.157
Authors: Atsushi Imai; Benjamin D Zeitlin; Fernanda Visioli; Zhihong Dong; Zhaocheng Zhang; Sudha Krishnamurthy; Emily Light; Frank Worden; Shaomeng Wang; Jacques E Nör Journal: Cancer Res Date: 2011-12-08 Impact factor: 12.701
Authors: Hui-Wen Lo; Lisa Stephenson; Xinyu Cao; Mira Milas; Raphael Pollock; Francis Ali-Osman Journal: Mol Cancer Res Date: 2008-05 Impact factor: 5.852
Authors: Paul L Swiecicki; Emily Bellile; Assuntina G Sacco; Alexander T Pearson; Jeremy M G Taylor; Trachette L Jackson; Douglas B Chepeha; Matthew E Spector; Andrew Shuman; Kelly Malloy; Jeffrey Moyer; Erin McKean; Scott McLean; Ammar Sukari; Gregory T Wolf; Avraham Eisbruch; Mark Prince; Carol Bradford; Thomas E Carey; Shaomeng Wang; Jacques E Nör; Francis P Worden Journal: Invest New Drugs Date: 2016-05-26 Impact factor: 3.850
Authors: Lulu Farhana; Marcia I Dawson; Farhan Murshed; Jayanta K Das; Arun K Rishi; Joseph A Fontana Journal: PLoS One Date: 2013-05-10 Impact factor: 3.240
Authors: Sanne R Martens-de Kemp; Simone U Dalm; Fiona M J Wijnolts; Arjen Brink; Richard J Honeywell; Godefridus J Peters; Boudewijn J M Braakhuis; Ruud H Brakenhoff Journal: PLoS One Date: 2013-04-17 Impact factor: 3.240